EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Molecular Mechanisms Underlying Atherosclerosis and Current Advances in Targeted Therapeutics

Bo Zhu iD

International Journal of Molecular Sciences · 08.01.2026 · 27 (2) · 634

DOI: 10.3390/ijms27020634 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 08.01.2026. Verfasst von Bo Zhu. Beteiligte Einrichtung: Vascular Biology Program, Boston Children's Hospital, Department of Surgery, Harvard Medical School, Boston, MA 02115, USA. Hauptthemen laut MEDLINE: Atherosclerosis, Molecular Targeted Therapy. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 183 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Atherosclerosis is a chronic, multifactorial vascular disease and the leading global cause of cardiovascular morbidity. Its development reflects interconnected disturbances in lipid metabolism, endothelial function, inflammation, smooth muscle cell (SMC) phenotypic switching, and extracellular matrix remodeling. Genetic predisposition, including monogenic disorders such as familial hypercholesterolemia and polygenic risk variants, modulates disease susceptibility by altering lipid homeostasis as well as inflammatory and thrombotic pathways. Epigenetic regulators and noncoding RNAs, such as histone modifications, microRNAs, and long noncoding RNAs, further shape gene expression and link environmental cues to vascular pathology. Endothelial injury promotes lipoprotein retention and oxidation, triggering monocyte recruitment and macrophage-driven foam cell formation, cytokine secretion, and necrotic core development. Persistent inflammation, macrophage heterogeneity, and SMC plasticity collectively drive plaque growth and destabilization. Emerging insights into immune cell metabolism, intracellular signaling networks, and novel regulatory RNAs are expanding therapeutic possibilities beyond lipid-lowering. Current and evolving treatments include statins, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, anti-inflammatory agents targeting interleukin-1 beta (IL-1β) or NOD-, LRR-, and pyrin domain-containing protein 3 (NLRP3), and advanced approaches such as gene editing, siRNA, and nanoparticle-based delivery. Integrating multi-omics, biomarker-guided therapy, and precision medicine promises improved risk stratification and next-generation targeted interventions. This review summarizes recent molecular advances and highlights translational opportunities for enhancing atherosclerosis prevention and treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AtherosclerosisMolecular Targeted TherapyHumansAnimalsLipid Metabolism

Stichwörter der Autor:innen

atherosclerosisendothelial dysfunctionfoam cellsinflammationlipid metabolismnon-coding RNAsmooth muscle cells

Autor:innen und Institutionen

  • Vascular Biology Program, Boston Children's Hospital, Department of Surgery, Harvard Medical School, Boston, MA 02115, USA.

ORCID-Profile: Bo Zhu

Zitieren

APA

Zhu, B. (2026). Molecular Mechanisms Underlying Atherosclerosis and Current Advances in Targeted Therapeutics. International Journal of Molecular Sciences, 27(2), 634. https://doi.org/10.3390/ijms27020634

Vancouver

Zhu B. Molecular Mechanisms Underlying Atherosclerosis and Current Advances in Targeted Therapeutics. International Journal of Molecular Sciences. 2026;27(2):634. doi:10.3390/ijms27020634

BibTeX
@article{Zhu2026,
  author = {Zhu, Bo},
  title = {Molecular Mechanisms Underlying Atherosclerosis and Current Advances in Targeted Therapeutics},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {2},
  pages = {634},
  doi = {10.3390/ijms27020634}
}
Kostenlos starten →